Patents Assigned to STELIC INSTITUTE & CO.
-
Patent number: 11911409Abstract: An object of the present invention is to develop a novel treatment method for chronic diseases for which conventional treatment methods are either ineffective or for which efficacy is low. The present invention provides a pharmaceutical composition for the treatment and/or prevention of an inflammatory chronic disease that is used in combination with a biological preparation that inhibits leukocyte tissue invasion. The pharmaceutical composition of the present invention contains as an active ingredient thereof siRNA suppressing the expression of CHST15 gene that contains a structure formed by the hybridization of RNA containing the base sequence represented by SEQ ID NO: 1 with RNA complementary thereto.Type: GrantFiled: October 20, 2021Date of Patent: February 27, 2024Assignee: STELIC INSTITUTE & CO., INC.Inventor: Hiroyuki Yoneyama
-
Patent number: 11485974Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: GrantFiled: May 8, 2020Date of Patent: November 1, 2022Assignees: STELIC INSTITUTE & CO., (NATIONAL UNIVERSITY CORPORATION) NIIGATA UNIVERSITY :Inventors: Hiroyuki Yoneyama, Kenji Suzuki
-
Publication number: 20220340910Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: June 3, 2022Publication date: October 27, 2022Applicant: STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Jun KOYAMA, Masato FUJII
-
Publication number: 20220323481Abstract: An object of the present invention is to develop a novel treatment method for chronic diseases for which conventional treatment methods are either ineffective or for which efficacy is low. The present invention provides a pharmaceutical composition for the treatment and/or prevention of an inflammatory chronic disease that is used in combination with a biological preparation that inhibits leukocyte tissue invasion. The pharmaceutical composition of the present invention contains as an active ingredient thereof siRNA suppressing the expression of CHST15 gene that contains a structure formed by the hybridization of RNA containing the base sequence represented by SEQ ID NO: 1 with RNA complementary thereto.Type: ApplicationFiled: October 20, 2021Publication date: October 13, 2022Applicant: STELIC INSTITUTE & CO., INC.Inventor: Hiroyuki YONEYAMA
-
Publication number: 20210108210Abstract: From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.Type: ApplicationFiled: December 9, 2020Publication date: April 15, 2021Applicant: STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Masato Fujii
-
Publication number: 20210040478Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: ApplicationFiled: May 8, 2020Publication date: February 11, 2021Applicants: STELIC INSTITUTE & CO., (NATIONAL UNIVERSITY CORPORATION) NIIGATA UNIVERSITYInventors: Hiroyuki YONEYAMA, Kenji SUZUKI
-
Patent number: 10689650Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: GrantFiled: February 6, 2019Date of Patent: June 23, 2020Assignees: STELIC INSTITUTE & CO., (NATIONAL UNIVERSITY CORPORATION) NIIGATA UNIVERSITYInventors: Hiroyuki Yoneyama, Kenji Suzuki
-
Publication number: 20200093850Abstract: An object of the present invention is to develop a novel treatment method for chronic diseases for which conventional treatment methods are either ineffective or for which efficacy is low. The present invention provides a pharmaceutical composition for the treatment and/or prevention of an inflammatory chronic disease that is used in combination with a biological preparation that inhibits leukocyte tissue invasion. The pharmaceutical composition of the present invention contains as an active ingredient thereof siRNA suppressing the expression of CHST15 gene that contains a structure formed by the hybridization of RNA containing the base sequence represented by SEQ ID NO: 1 with RNA complementary thereto.Type: ApplicationFiled: December 7, 2017Publication date: March 26, 2020Applicant: STELIC INSTITUTE & CO., INC.Inventor: Hiroyuki YONEYAMA
-
Publication number: 20190376063Abstract: From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.Type: ApplicationFiled: June 19, 2019Publication date: December 12, 2019Applicant: STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Masato FUJII
-
Publication number: 20190330637Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: January 2, 2019Publication date: October 31, 2019Applicant: STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Jun Koyama, Masato Fujii
-
Publication number: 20190153447Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: ApplicationFiled: February 6, 2019Publication date: May 23, 2019Applicants: STELIC INSTITUTE & CO., (NATIONAL UNIVERSITY CORPORATION) NIIGATA UNIVERSITYInventors: Hiroyuki YONEYAMA, Kenji SUZUKI
-
Publication number: 20170260533Abstract: From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Applicant: STELIC INSTITUTE & CO.Inventors: HIROYUKI YONEYAMA, MASATO FUJII
-
Patent number: 9596834Abstract: Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.Type: GrantFiled: February 27, 2014Date of Patent: March 21, 2017Assignee: Stelic Institute of Regenerative Medicine, Stelic Institute & Co.Inventors: Hiroyuki Yoneyama, Masato Fujii
-
Publication number: 20170067058Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: July 21, 2016Publication date: March 9, 2017Applicant: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Jun KOYAMA, Masato FUJII
-
Publication number: 20160355818Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: ApplicationFiled: August 19, 2016Publication date: December 8, 2016Applicants: Stelic Institute of Regenerative Medicine, Stelic Institute & Co., Niigata UniversityInventors: HIROYUKI YONEYAMA, Kenji SUZUKI
-
Publication number: 20160348118Abstract: From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.Type: ApplicationFiled: August 15, 2016Publication date: December 1, 2016Applicant: STELIC INSTITUTE & CO.Inventors: HIROYUKI YONEYAMA, MASATO FUJII
-
Publication number: 20150337313Abstract: From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.Type: ApplicationFiled: July 17, 2012Publication date: November 26, 2015Applicant: STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Masato FUJII
-
Publication number: 20150290238Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: May 5, 2015Publication date: October 15, 2015Applicant: Stelic Institute of Regenerative Medicine, Stelic Institute & Co.Inventors: Hiroyuki YONEYAMA, Jun KOYAMA, Masato FUJII
-
Publication number: 20140178306Abstract: Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.Type: ApplicationFiled: February 27, 2014Publication date: June 26, 2014Applicant: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO.Inventors: HIROYUKI YONEYAMA, MASATO FUJII
-
Publication number: 20140135379Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicants: NIIGATA UNIVERSITY, Stelic Institute of Regenerative Medicine, Stelic Institute & CO.Inventors: Hiroyuki YONEYAMA, Kenji SUZUKI